Do we need to redefine the advanced stage in Parkinson's disease?

被引:0
|
作者
Sesar, Angel [1 ]
Fernandez-Pajarin, Gustavo [1 ]
Ares, Begona [1 ]
Castro, Alfonso [1 ]
机构
[1] Hosp Clin Univ, Movement Disorder Unit, Neurol Dept, Santiago De Compostela, Spain
来源
REVISTA MEXICANA DE NEUROCIENCIA | 2021年 / 22卷 / 04期
关键词
Parkinson's disease; Advanced stage; Post-advanced stage; Dopaminergic symptoms; Non-dopaminergic symptoms; SYDNEY MULTICENTER; SYMPTOMS;
D O I
10.24875/RMN.20000119
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Identifying the advanced stage in Parkinson's disease ( PD) is crucial for shifting from conventional to device-aided therapies. The criteria to define the onset of advanced PD have been based on lengthy and disabling daily off-times, troublesome dyskinesia and complex therapeutic regimes, but have also included invalidating non-dopaminergic symptoms, such as dementia, falls or dysphagia. These last problems usually appear in a much later stage of the advanced PD. The key to the definition of advanced PD should be the lack of adequate PD control of both motor and non-motor dopaminergic symptoms. The patient's judgment about the quality of their response to conventional therapy is also critical to establish the advanced stage. The early identification of this phase allows maintaining the patient's functional state whenever appropriate treatments are applied. We should keep the term advanced stage when the dopaminergic symptoms responsive to device-aided therapy are preponderant. When invalidating non-dopaminergic symptoms dominate the clinical picture, the term post-advanced stage could be more suitable.
引用
收藏
页码:152 / 158
页数:7
相关论文
共 50 条
  • [31] Personalizing decision-making for persons with Parkinson's disease: where do we stand and what to improve?
    van den Heuvel, Lieneke
    Meinders, Marjan J.
    Post, Bart
    Bloem, Bastiaan R.
    Stiggelbout, Anne M.
    JOURNAL OF NEUROLOGY, 2022, 269 (07) : 3569 - 3578
  • [32] Parkinson's Disease: We Care!
    Bloem, Bastiaan R.
    Brundin, Patrik
    JOURNAL OF PARKINSONS DISEASE, 2020, 10 : S1 - S3
  • [33] Advanced Parkinson's or "complex phase" Parkinson's disease? Re-evaluation is needed
    Titova, Nataliya
    Martinez-Martin, Pablo
    Katunina, Elena
    Chaudhuri, K. Ray
    JOURNAL OF NEURAL TRANSMISSION, 2017, 124 (12) : 1529 - 1537
  • [34] Treatment of advanced Parkinson's disease
    Giugni, Juan C.
    Okun, Michael S.
    CURRENT OPINION IN NEUROLOGY, 2014, 27 (04) : 450 - 460
  • [35] What Do We Know about Theory of Mind Impairment in Parkinson's Disease?
    Trompeta, Clara
    Fernandez Rodriguez, Beatriz
    Gasca-Salas, Carmen
    BEHAVIORAL SCIENCES, 2021, 11 (10)
  • [36] THE TREATMENT OF ADVANCED PARKINSON'S DISEASE
    Klivenyi Peter
    Vecsei Laszlo
    IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, 2018, 71 (11-12): : 377 - 383
  • [37] Clinical problems in late-stage Parkinson's disease
    Gershanik, Oscar S.
    JOURNAL OF NEUROLOGY, 2010, 257 : S288 - S291
  • [38] Living with advanced Parkinson's disease: a constant struggle with unpredictability
    Haahr, Anita
    Kirkevold, Marit
    Hall, Elisabeth O. C.
    Ostergaard, Karen
    JOURNAL OF ADVANCED NURSING, 2011, 67 (02) : 408 - 417
  • [39] Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease
    Bruno, Veronica
    Freitas, Maria Eliza
    Mancini, Deborah
    Lui, Jane P.
    Miyasaki, Janis
    Fox, Susan H.
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2018, 45 (01) : 23 - 29
  • [40] Functional connectivity markers of depression in advanced Parkinson's disease
    Lin, Hai
    Cai, Xiaodong
    Zhang, Doudou
    Liu, Jiali
    Na, Peng
    Li, Weiping
    NEUROIMAGE-CLINICAL, 2020, 25